Study S002229

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in Non-Diabetic Obese Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A Retrospective Real-World Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07846956
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 28
Start: 2026-09-21
Primary completion: 2026-11-30
Lead sponsor: Istanbul Saglik Bilimleri University
Conditions: Non-arteritic Anterior Ischemic Optic Neuropathy Obesity; Obesity
Interventions: DRUG:GLP-1 Receptor Agonist Therapy
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Occurrence of NAION [Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002696	Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration. Allan KC, Ophthalmology	2025	Nonrandomized study	PMID 39863057 DOI	registry reference BACKGROUND:39863057
R0006186	Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Hathaway JT, JAMA ophthalmology	2024	Nonrandomized study	PMID 38958939 DOI	registry reference BACKGROUND:38958939
R0003898	Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications. Liu H, European review for medical and pharmacological sciences	2023	Narrative review	PMID 37013752 DOI	registry reference BACKGROUND:37013752
R0004204	GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Kapoor I, Survey of ophthalmology	2023	Systematic review	PMID 37454782 DOI	registry reference BACKGROUND:37454782
R0008912	Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Aroda VR, Diabetes, obesity & metabolism	2023	Randomized trial	PMID 36700417 DOI	registry reference RESULT:36700417